FOLH1 and neoplasm: This notable difference in patient’s median OS between these 2 studies might either reflect the disparity of the patient’s population and their tumor burden as our study included almost 30% chemotherapy naïve patients, while in Rahbar et al., the entire studied cohort was previously treated with chemotherapy or points towards a superior efficacy of high doses of 3 cycles PSMA-RTL in short 4-week interval.